DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis

Information source: Dattoli Cancer Center and Brachytherapy Research Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Prostate Cancer Patients Undergoing External Radiation and Seed Implantation

Phase: N/A

Status: Completed

Sponsored by: Dattoli Cancer Center and Brachytherapy Research Institute

Official(s) and/or principal investigator(s):
Michael J Dattoli, MD, Principal Investigator, Affiliation: Dattoli Cancer Center and Brachytherapy Research Institute

Summary

In the past ten years, newer drugs with more selective affinity for the alpha-receptor have been introduced. Alfuzosin (Uroxatral) and Tamulosin(Flomax are two second generation alpha-blockers. In the course of our clinical proctice, both drugs have been used routinely. This retrospective comparison is intended to be a priliminary comparison of their effectiveness and side effects.

Clinical Details

Official title: Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs Twice Daily Dosing of Flomax-A 3 Month Retrospective Efficacy Analysis

Study design: Observational Model: Defined Population, Time Perspective: Longitudinal

Eligibility

Minimum age: 45 Years. Maximum age: 80 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Males age 45-80 years

- Diagnosis of prostate cancer

- Status post IMRT and Palladium-103 seed implantation and initiated alpha blocker

therapy with alfuzosin10mg daily or tamulosin 0. 4mg bid at time of seed implantation

- Baseline AUA score< or =12

- May be on antiandrogenand/or alpha reductase therapy

- Patients receiving IMRT followed by Palladium-103 Brachytherapy implantation as the

primary therapy for prostate cancer with curatives intent -

Exclusion Criteria:

- History of insulin-dependent diabetes

- Uncontrolled hypertention

- History of symptomtic hypotension (including syncope and dizziness)

- Pre-existing obstructive uropathy based on history of BPH and or Acute Urinary

Retention

- Pre-existing prostatitis either continuous or intermittent

- Concurrent use of any other anticholinergics

- previous or concurrent usage of LHRH agonist

Locations and Contacts

Dattoli Cancer Center and Brachytherapy Research Institute, Sarasota, Florida 34237, United States
Additional Information

Starting date: November 2005
Last updated: December 6, 2005

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017